ACM
TRML

Altium Capital Management’s Tourmaline Bio TRML Stock Holding History

Altium Capital Management’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-65,442
Closed -$1.5M – 81
2024
Q1 		$1.5M Buy
+65,442
New +$2.31M 0.59% 38

Other funds holding TRML

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Altium Capital Management's TRML Position: Q2 2024 in Review

Altium Capital Management sold out of Tourmaline Bio (TRML) in Q2 2024, closing a stake of 65,442 shares — an estimated $1.5M sold.

Altium Capital Management first reported a position in TRML in Q1 2024 and held it in 1 quarter. The position peaked at $1.5M in Q1 2024. 84 funds tracked by Wall St. Rank hold TRML as of Q2 2024.

  • Altium Capital Management reported no remaining Tourmaline Bio position as of Q2 2024 after selling out during the quarter.
  • Altium Capital Management sold 65,442 Tourmaline Bio shares in Q2 2024, an estimated $1.5M.
  • Altium Capital Management first reported a position in Tourmaline Bio in Q1 2024 and held it in 1 quarter.
  • Altium Capital Management's Tourmaline Bio position peaked at $1.5M in Q1 2024.
  • 84 funds tracked by Wall St. Rank held Tourmaline Bio as of Q2 2024.

Based on Altium Capital Management's 13F filing for Q2 2024, filed 15 Aug 2024.